These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

1199 related items for PubMed ID: 18179782

  • 41. Characterization of SR 121463A, a highly potent and selective, orally active vasopressin V2 receptor antagonist.
    Serradeil-Le Gal C, Lacour C, Valette G, Garcia G, Foulon L, Galindo G, Bankir L, Pouzet B, Guillon G, Barberis C, Chicot D, Jard S, Vilain P, Garcia C, Marty E, Raufaste D, Brossard G, Nisato D, Maffrand JP, Le Fur G.
    J Clin Invest; 1996 Dec 15; 98(12):2729-38. PubMed ID: 8981918
    [Abstract] [Full Text] [Related]

  • 42. Renal effects of angiotensin-converting enzyme inhibition in cardiac failure.
    Dzau VJ.
    Am J Kidney Dis; 1987 Jul 15; 10(1 Suppl 1):74-80. PubMed ID: 3037893
    [Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44. Negative modulation of nitric oxide production by neurotensin as a putative mechanism of the diuretic action of SR 48692 in rats.
    Croci T, Landi M, Gully D, Maffrand JP, Le Fur G, Manara L.
    Br J Pharmacol; 1997 Apr 15; 120(7):1312-8. PubMed ID: 9105707
    [Abstract] [Full Text] [Related]

  • 45. Aquaretic effect of lixivaptan, an oral, non-peptide, selective V2 receptor vasopressin antagonist, in New York Heart Association functional class II and III chronic heart failure patients.
    Abraham WT, Shamshirsaz AA, McFann K, Oren RM, Schrier RW.
    J Am Coll Cardiol; 2006 Apr 18; 47(8):1615-21. PubMed ID: 16630999
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Anti-edematous effects of tolvaptan in experimental rodent models.
    Miyazaki T, Sakamoto Y, Yamashita T, Ohmoto K, Fujiki H.
    Cardiovasc Drugs Ther; 2011 Dec 18; 25 Suppl 1():S77-82. PubMed ID: 22120096
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49. Different effects of long- and short-acting loop diuretics on survival rate in Dahl high-salt heart failure model rats.
    Yoshida J, Yamamoto K, Mano T, Sakata Y, Nishio M, Ohtani T, Hori M, Miwa T, Masuyama T.
    Cardiovasc Res; 2005 Oct 01; 68(1):118-27. PubMed ID: 16002057
    [Abstract] [Full Text] [Related]

  • 50. Heart failure and electrolyte disturbances.
    Schwinger RH, Erdmann E.
    Methods Find Exp Clin Pharmacol; 1992 May 01; 14(4):315-25. PubMed ID: 1507935
    [Abstract] [Full Text] [Related]

  • 51. Vasopressin and vasopressin receptor antagonists in heart failure.
    Oghlakian G, Klapholz M.
    Cardiol Rev; 2009 May 01; 17(1):10-5. PubMed ID: 19092365
    [Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53. Vasopressin excess and hyponatremia.
    Pham PC, Pham PM, Pham PT.
    Am J Kidney Dis; 2006 May 01; 47(5):727-37. PubMed ID: 16632011
    [Abstract] [Full Text] [Related]

  • 54. Arginine vasopressin receptor antagonists (vaptans): pharmacological tools and potential therapeutic agents.
    Veeraveedu PT, Palaniyandi SS, Yamaguchi K, Komai Y, Thandavarayan RA, Sukumaran V, Watanabe K.
    Drug Discov Today; 2010 Oct 01; 15(19-20):826-41. PubMed ID: 20708094
    [Abstract] [Full Text] [Related]

  • 55. Effects of long-term treatment with enalapril or hydralazine on the renin-angiotensin-aldosterone system and fluid balance in dogs with naturally acquired mitral valve regurgitation.
    Häggström J, Hansson K, Karlberg BE, Kvart C, Madej A, Olsson K.
    Am J Vet Res; 1996 Nov 01; 57(11):1645-52. PubMed ID: 8915446
    [Abstract] [Full Text] [Related]

  • 56. Effects of tolvaptan on volume overload in Japanese patients with heart failure: results of a phase II, multicenter, randomized, double-blind, placebo-controlled, parallel-group study.
    Matsuzaki M, Hori M, Izumi T, Asanoi H, Tsutamoto T, Tolvaptan Investigators.
    Cardiovasc Drugs Ther; 2011 Dec 01; 25 Suppl 1():S19-31. PubMed ID: 22120091
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 59.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 60.